The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
Open accessAbstract
Epithelial-to-mesenchymal transition (EMT) is a process that plays essential roles in development and wound healing that is characterized by loss of homotypic adhesion and cell polarity and increased invasion and migration. At the molecular level, EMT is characterized by loss of E-cadherin and increased expression of several transcriptional repressors of E-cadherin expression (Zeb-1, Zeb-2, Twist, Snail, and Slug). Early work established that loss of E-cadherin and increased expression of MMP-9 was associated with a poor clinical outcome in patients with urothelial tumors, suggesting that EMT might also be associated with bladder cancer progression and metastasis. More recently, we have used global gene expression profiling to characterize the molecular heterogeneity in human urothelial cancer cell lines (n = 20) and primary patient tumors, and unsupervised clustering analyses revealed that the cells naturally segregate into two discrete “epithelial” and “mesenchymal” subsets, the latter consisting entirely of muscle-invasive tumors. Importantly, sensitivity to inhibitors of the epidermal growth factor receptor (EGFR) or type-3 fibroblast growth factor receptor (FGFR3) was confined to the “epithelial” subset, and sensitivity to EGFR inhibitors could be reestablished by micro-RNA-mediated molecular reversal of EMT. The results suggest that EMT coordinately regulates drug resistance and muscle invasion/metastasis in urothelial cancer and is a dominant feature of overall cancer biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
(2015) · American Journal Of Pathology · doi:10.2353/ajpath · Cited by 4,908
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“colon cancers resistant to EGFR-directed therapy [53, 60, 61].”
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,389
International Journal of Oncology
(2026) · International Journal of Oncology · doi:10.3892/ijo · Cited by 2,331
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272 · cited 8×
“Members of the family bind directly to the mRNAs encoding Zeb-1 and Zeb-2, promoting their degradation and blocking translation.”
BackgroundInfluentialLoss of E-Cadherin Promotes Metastasis via Multiple Downstream Transcriptional Pathways
Onder, T. T., Gupta, P. B., Mani, S. A., Yang, J., Lander, E. S., & Weinberg, R. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2938 · Cited by 1,522
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,461
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
SMAD proteins control DROSHA-mediated microRNA maturation
Davis, B. N., Hilyard, A. C., Lagna, G., & Hata, A. (2008) · Nature · doi:10.1038/nature07086 · Cited by 1,244
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Arumugam, T., Ramachandran, V., Fournier, K. F., Wang, H., Marquis, L., Abbruzzese, J. L., Gallick, G. E., Logsdon, C. D., McConkey, D. J., & Choi, W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2819 · Cited by 863
Self-citationEpidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673
Zhu, C.-Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.-C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8924 · Cited by 661
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., & Dinney, C. P. (1999) · PubMed · Cited by 647
Self-citationWagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Totpal, K., et al. (2007) · Nature Medicine · doi:10.1038/nm1627 · Cited by 612
p63 Is a Prostate Basal Cell Marker and Is Required for Prostate Development
Signoretti, S., Waltregny, D., Dilks, J., Isaac, B., Lin, D., Garraway, L., Yang, A., Montironi, R., McKeon, F., & Loda, M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64814-6 · Cited by 610
p63 expression profiles in human normal and tumor tissues.
Como, C. J. D., Urist, M. J., Babayan, I., Drobnjak, M., Hedvat, C. V., Teruya‐Feldstein, J., Kamal, P., Hoos, A., & Cordon‐Cardo, C. (2002) · PubMed · Cited by 579
Sanchez-Carbayo, M., Socci, N. D., Lozano, J., Saint, F., & Cordon-Cardo, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2375 · Cited by 550
Witta, S. E., Gemmill, R. M., Hirsch, F. R., Coldren, C. D., Hedman, K., Ravdel, L., Helfrich, B., Dziadziuszko, R., Chan, D. C., Sugita, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1988 · Cited by 515
Gibbons, D. L., Lin, W., Creighton, C. J., Rizvi, Z. H., Gregory, P. A., Goodall, G. J., Thilaganathan, N., Du, L., Zhang, Y., Pertsemlidis, A., et al. (2009) · Genes & Development · doi:10.1101/gad.1820209 · Cited by 512
Adam, L., Zhong, M., Choi, W., Qi, W., Nicoloso, M., Arora, A., Calin, G., Wang, H., Siefker-Radtke, A., McConkey, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2245 · Cited by 412
Self-citationJänne, P. A., Engelman, J. A., & Johnson, B. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.985 · Cited by 405
Dichotomy of astrocytoma migration and proliferation
Giese, A., Loo, M. A., Tran, N., Haskett, D., Coons, S. W., & Berens, M. E. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960717)67:2<275::aid-ijc20>3.0.co;2-9 · Cited by 399
Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., Furnari, F. B., & White, F. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705158104 · Cited by 390
Hurteau, G. J., Carlson, J. A., Spivack, S. D., & Brock, G. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1058 · Cited by 390
Cadherin and catenin alterations in human cancer
Hajra, K. M., & Fearon, E. R. (2002) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10083 · Cited by 380
Tomlinson, D., Baldo, O., Harnden, P., & Knowles, M. (2007) · The Journal of Pathology · doi:10.1002/path.2207 · Cited by 363
Levy, L., & Hill, C. S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.18.8108-8125.2005 · Cited by 342
Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., & Fidler, I. J. (1999) · PubMed · Cited by 337
Self-citationBladder Cancer Outcome and Subtype Classification by Gene Expression
Blaveri, E., Simko, J. P., Korkola, J. E., Brewer, J. L., Baehner, F., Mehta, K., DeVries, S., Koppie, T., Pejavar, S., Carroll, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2409 · Cited by 337
Eberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 300
Miller, V. A., Riely, G. J., Zakowski, M. F., Li, A. R., Patel, J. D., Heelan, R. T., Kris, M. G., Sandler, A. B., Carbone, D. P., Tsao, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0062 · Cited by 297
Dinney, C. P. N., McConkey, D. J., Millikan, R. E., Wu, X., Bar-Eli, M., Adam, L., Kamat, A. M., Siefker-Radtke, A. O., Tuziak, T., Sabichi, A. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.002 · Cited by 290
Self-citationDinney, C. P., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., BUCANA, C. D., & Fidler, I. J. (1998) · PubMed · Cited by 271
Self-citationLoss of p63 Expression Is Associated with Tumor Progression in Bladder Cancer
Urist, M. J., Di Como, C. J., Lu, M.-L., Charytonowicz, E., Verbel, D., Crum, C. P., Ince, T. A., McKeon, F. D., & Cordon-Cardo, C. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64396-9 · Cited by 257
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38017 · Cited by 255
G�rtner, F., Schmitt, F. C., Preto, A., Reis-Filho, J. S., Simpson, P. T., & Martins, A. (2003) · Virchows Archiv · doi:10.1007/s00428-003-0859-2 · Cited by 235
Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix
Honn, K. V., & Tang, D. G. (1992) · Cancer and Metastasis Reviews · doi:10.1007/bf01307187 · Cited by 227
Role of Ras Signaling in the Induction of Snail by Transforming Growth Factor-β
Horiguchi, K., Shirakihara, T., Nakano, A., Imamura, T., Miyazono, K., & Saitoh, M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804777200 · Cited by 219
Frequent alteration of p63 expression in human primary bladder carcinomas.
Park, B.-J., Lee, S. J., Kim, J. I., Lee, S., Lee, C. H., Chang, S. G., Park, J. H., & Chi, S. G. (2000) · PubMed · Cited by 209
Hirsch, F. R., Scagliotti, G. V., Langer, C. J., Varella-Garcia, M., & Franklin, W. A. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00137-5 · Cited by 208
Kim, S. J., Uehara, H., Karashima, T., Mccarty, M., Shih, N., & Fidler, I. J. (2001) · Neoplasia · doi:10.1038/sj.neo.7900124 · Cited by 206
Slaton, J. W., Inoue, K., Perrotte, P., El-Naggar, A. K., Swanson, D. A., Fidler, I. J., & Dinney, C. P. N. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64016-3 · Cited by 195
Self-citationEpigenetic versus genetic alterations in the inactivation of E-cadherin
Strathdee, G. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00057-3 · Cited by 192
Sayan, A. E., Griffiths, T. R., Pal, R., Browne, G. J., Ruddick, A., Yagci, T., Edwards, R., Mayer, N. J., Qazi, H., Goyal, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902042106 · Cited by 192
Baumgart, E., Cohen, M. S., Neto, B. S., Jacobs, M. A., Wotkowicz, C., Rieger-Christ, K. M., Biolo, A., Zeheb, R., Loda, M., Libertino, J. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2330 · Cited by 192
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
Ludwig, A. T., Moore, J. M., Luo, Y., Chen, X., Saltsgaver, N. A., O’Donnell, M. A., & Griffith, T. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0374 · Cited by 186
Koga, F., Kawakami, S., Fujii, Y., Saito, K., Ohtsuka, Y., Iwai, A., Ando, N., Takizawa, T., Kageyama, Y., & Kihara, K. (2003) · PubMed · Cited by 181
Proliferation Versus Migration in Platelet-derived Growth Factor Signaling
Donatis, A. D., Comito, G., Buricchi, F., Vinci, M. C., Parenti, A., Caselli, A., Camici, G., Manao, G., Ramponi, G., & Cirri, P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709428200 · Cited by 178
p63 regulates commitment to the prostate cell lineage
Signoretti, S., Pires, M. M., Lindauer, M., Horner, J. W., Grisanzio, C., Dhar, S., Majumder, P. K., McKeon, F., Kantoff, P. W., Sellers, W. R., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500165102 · Cited by 153
Label-retaining cells of the bladder: candidate urothelial stem cells
Kurzrock, E. A., Lieu, D. K., deGraffenried, L. A., Chan, C. W. Y., & Isseroff, R. R. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00533.2007 · Cited by 141
Kemp, T. J., Ludwig, A. T., Earel, J. K., Moore, J. M., VanOosten, R. L., Moses, B., Leidal, K. G., Nauseef, W. M., & Griffith, T. S. (2005) · Blood · doi:10.1182/blood-2005-03-1327 · Cited by 129
Kuniyasu, H., Troncoso, P., Johnston, D., Bucana, C. D., Tahara, E., Fidler, I. J., & Pettaway, C. A. (2000) · PubMed · Cited by 129
Role of neutrophils in BCG immunotherapy for bladder cancer
Simons, M. P., O’Donnell, M. A., & Griffith, T. S. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.11.031 · Cited by 129
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
Tomlinson, D. C., Hurst, C. D., & Knowles, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210399 · Cited by 128
Kuniyasu, H., Ellis, L. M., Evans, D. B., Abbruzzese, J. L., Fenoglio, C. J., Bucana, C. D., Cleary, K. R., Tahara, E., & Fidler, I. J. (1999) · PubMed · Cited by 124
Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer
Lara-Guerra, H., Waddell, T. K., Salvarrey, A. M., Joshua, A. M., Chung, C. T. ‐., Paul, N., Boerner, S. L., Sakurada, A., Ludkovski, O., Ma, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3370 · Cited by 117
Herbst, R. S., Yano, S., Kuniyasu, H., Khuri, F. R., Bucana, C. D., Guo, F., Liu, D., Kemp, B. L., Lee, J. J., Hong, W. K., et al. (2000) · PubMed · Cited by 116
Black, P. C., Brown, G. A., Inamoto, T., Shrader, M., Arora, A., Siefker-Radtke, A. O., Adam, L., Theodorescu, D., Wu, X., Munsell, M. F., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1593 · Cited by 109
Self-citationp63: revving up epithelial stem-cell potential
Blanpain, C., & Fuchs, E. V. (2007) · Nature Cell Biology · doi:10.1038/ncb0707-731 · Cited by 102
Izawa, J. I., Sweeney, P., Perrotte, P., Kedar, D. J., Dong, Z., Slaton, J. W., Karashima, T., Inoue, K., Benedict, W. F., & Dinney, C. P. (2002) · PubMed · Cited by 95
Self-citationKassouf, W., Dinney, C. P., Brown, G. A., McConkey, D. J., Diehl, J. A., Bar‐Eli, M., & Adam, L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1536 · Cited by 92
Self-citationCheng, J. Q., Huang, H., Zhang, Z.-T., Shapiro, E., Pellicer, À., Sun, T., & Wu, X. (2002) · PubMed · Cited by 92
Heymach, J. V., Nilsson, M. B., Blumenschein, G., Papadimitrakopoulou, V. A., & Herbst, R. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0286 · Cited by 88
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours
Sibley, K., Stern, P., & Knowles, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204543 · Cited by 88
Kitadai, Y., Ellis, L. M., Tucker, S. L., Greene, G. F., Bucana, C. D., Cleary, K. R., Takahashi, Y., Tahara, E., & Fidler, I. J. (1996) · Europe PMC (PubMed Central) · Cited by 87
Shrader, M., Pino, M. S., Lashinger, L. M., Bar‐Eli, M., Adam, L., Dinney, C. P., & McConkey, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1224 · Cited by 85
Self-citationPapageorgiou, A., Dinney, C. P., & McConkey, D. J. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.6.4088 · Cited by 81
Self-citationSlaton, J. W., Millikan, R. E., Inoue, K., Karashima, T., Czerniak, B. A., Shen, Y., Yang, Y., Benedict, W. F., & Dinney, C. P. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000108845.91485.20 · Cited by 80
Self-citationEngel, M. E., Datta, P. K., & Moses, H. L. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1998)72:30/31+<111::aid-jcb15>3.0.co;2-5 · Cited by 69
Puig, P., Capodieci, P., Drobnjak, M., Verbel, D., Prives, C. L., Cordon‐Cardo, C., & Como, C. J. D. (2003) · PubMed · Cited by 69
Blehm, K., Spiess, P. E., Bondaruk, J. E., Dujka, M. E., Villares, G. J., Zhao, Y.-J., Bögler, O., Aldape, K., Grossman, H. B., Adam, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0407 · Cited by 69
Self-citationMolecular correlates of gefitinib responsiveness in human bladder cancer cells
Shrader, M., Pino, M. S., Brown, G. A., Black, P. C., Adam, L., Bar-Eli, M., Dinney, C. P., & McConkey, D. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0513 · Cited by 68
Self-citationSlaton, J. W., Karashima, T., Perrotte, P., Inoue, K., Kim, S. J., Izawa, J. I., Kedar, D. J., McConkey, D. J., Millikan, R. E., Sweeney, P., et al. (2001) · PubMed · Cited by 63
Self-citationNeutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer
Simons, M. P., Nauseef, W. M., & Griffith, T. S. (2007) · Immunologic Research · doi:10.1007/s12026-007-0084-1 · Cited by 46
Defining Cell Lineages in the Prostate Epithelium
Signoretti, S., & Loda, M. F. (2005) · Cell Cycle · doi:10.4161/cc.5.2.2340 · Cited by 43
Simons, M. P., Moore, J. M., Kemp, T. J., & Griffith, T. S. (2006) · Infection and Immunity · doi:10.1128/iai.00938-06 · Cited by 43
Expression of metastasis-related genes in human epithelial ovarian tumors
Herrera, C., Xu, L., Bucana, C. D., Silva, E., Hess, K. R., Gershenson, D. M., & Fidler, I. J. (2002) · International Journal of Oncology · doi:10.3892/ijo.20.1.5 · Cited by 38
ANZAI, H., Kitadai, Y., Bucana, C. D., Sanchez, R. R., Omoto, R., & Fidler, I. J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10075-2 · Cited by 35
Papageorgiou, A., Kamat, A. M., Benedict, W. F., Dinney, C. P., & McConkey, D. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0474 · Cited by 35
Self-citation
Cited by
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Du, B., & Shim, J. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 807
EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness
Sánchez-Tilló, E., Liu, Y., de Barrios, O., Siles, L., Fanlo, L., Cuatrecasas, M., Darling, D. S., Dean, D. C., Castells, A., & Postigo, A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1122-2 · Cited by 518
Haslehurst, A. M., Koti, M., Dharsee, M., Nuin, P., Evans, K., Geraci, J., Childs, T., Chen, J., Li, J., Weberpals, J., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-91 · Cited by 402
Epithelial–mesenchymal transition: a new target in anticancer drug discovery
Marcucci, F., Stassi, G., & De Maria, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 342
Epithelial-mesenchymal Transition and Cell Invasion
Son, H.-J., & Moon, A. (2010) · Toxicological Research · doi:10.5487/tr.2010.26.4.245 · Cited by 320
Metadata
- Authors
- McConkey, D. J., Choi, W., Marquis, L., Martin, F., Williams, M. B., Shah, J., Svatek, R., Das, A., Adam, L., Kamat, A., Siefker-Radtke, A., & Dinney, C.
- Venue
- Cancer and Metastasis Reviews
- Published
- 2009-12
- Volume
- 28
- Issue
- 3-4
- Pages
- 335-344
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- OpenAlex
- W2078134150
- Cited by
- 368
- References
- 84
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.